By Dr. Liji Thomas, MDAug 16 2022Reviewed by Benedette Cuffari, M.Sc. The severe acute respiratory syndrome coronavirus 2 continues to be transmitted throughout the world following its initial identification in Wuhan, China, at the end of December 2019. Despite the development of vaccines against SARS-CoV-2, several new variants with escape mutations have emerged that are capable of resisting neutralization by antibodies elicited by infection with previous variants.
The current study reports the effects of vaccination on viral adaptive mutations. These types of mutations arise as a result of errors in viral genome replication or because of damage to or editing of the viral ribonucleic acid . These mutations may become fixed, either by genetic drift, a stochastic process, or natural selection.
The researchers also explored the Alpha, Delta, Omicron, as well as other SARS-CoV-2 variants that were not designated as variants of concern , as well as BTIs after vaccination with either the Pfizer/BioNTech messenger ribonucleic acid vaccine or CoronaVac vaccines. RNA editing/damage-associated changes were observed and may be the result of an overabundance of reactive oxygen species .
The nucleotide diversity was also higher as compared to unvaccinated non-VOC samples. For unvaccinated non-VOCs, this measure showed excess synonymous polymorphism, which was a sign of purifying selection at the whole-genome level. This was not observed for unvaccinated VOC samples. The higher iSNV incidence in BTI samples following a primary vaccination is observed for the Delta VOC but not Omicron. While this might be due to a longer time lapse between the second dose of the vaccine and sampling date in Omicron patients, it could also be the result of increased neutralizing antibody titers against Delta as compared to Omicron.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A non-covalent inhibitor of 3C-like protease effectively inhibits SARS-CoV-2 replicationA non-covalent inhibitor of 3C-like protease effectively inhibits SARS-CoV-2 replication biorxivpreprint utmbhealth SARSCoV2 COVID19 coronavirus covid protease inhibitor enzyme replication
Source: NewsMedical - 🏆 19. / 71 Read more »
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study - BMC Infectious DiseasesBackground Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still urgently needed. Several antiviral drugs have shown to be effective in reducing progression of COVID-19 disease. Methods In the present work, we use an agent-based mathematical model to assess the potential population impact of the use of antiviral treatments in four countries with different demographic structure and current levels of vaccination coverage: Kenya, Mexico, United States (US) and Belgium. We analyzed antiviral effects on reducing hospitalization and death, and potential antiviral effects on reducing transmission. For each country, we varied daily treatment initiation rate (DTIR) and antiviral effect in reducing transmission (AVT). Results Irrespective of location and AVT, widespread antiviral treatment of symptomatic adult infections (20% DTIR) prevented the majority of COVID-19 deaths, and recruiting 6% of all adult symptomatic infections daily reduced mortality by over 20% in all countries. Furthermore, our model projected that targeting antiviral treatment to the oldest age group (65 years old and older, DTIR of 20%) can prevent over 30% of deaths. Our results suggest that early antiviral treatment (as soon as possible after inception of infection) is needed to mitigate transmission, preventing 50% more infections compared to late treatment (started 3 to 5 days after symptoms onset). Our results highlight the synergistic effect of vaccination and antiviral treatment: as the vaccination rate increases, antivirals have a larger relative impact on population transmission. Finally, our model projects that even in highly vaccinated populations, adding antiviral treatment can be extremely helpful to mitigate COVID-19 deaths. Conclusions These results suggest that antiviral treatments can become a strategic tool that, in combination with vaccination, can significantly reduce COVID-19 hospitalizations and deaths and can help control SARS-Co
Source: BioMedCentral - 🏆 22. / 71 Read more »
A non-covalent inhibitor of 3C-like protease effectively inhibits SARS-CoV-2 replicationA non-covalent inhibitor of 3C-like protease effectively inhibits SARS-CoV-2 replication biorxivpreprint utmbhealth SARSCoV2 COVID19 coronavirus covid protease inhibitor enzyme replication
Source: NewsMedical - 🏆 19. / 71 Read more »
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study - BMC Infectious DiseasesBackground Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still urgently needed. Several antiviral drugs have shown to be effective in reducing progression of COVID-19 disease. Methods In the present work, we use an agent-based mathematical model to assess the potential population impact of the use of antiviral treatments in four countries with different demographic structure and current levels of vaccination coverage: Kenya, Mexico, United States (US) and Belgium. We analyzed antiviral effects on reducing hospitalization and death, and potential antiviral effects on reducing transmission. For each country, we varied daily treatment initiation rate (DTIR) and antiviral effect in reducing transmission (AVT). Results Irrespective of location and AVT, widespread antiviral treatment of symptomatic adult infections (20% DTIR) prevented the majority of COVID-19 deaths, and recruiting 6% of all adult symptomatic infections daily reduced mortality by over 20% in all countries. Furthermore, our model projected that targeting antiviral treatment to the oldest age group (65 years old and older, DTIR of 20%) can prevent over 30% of deaths. Our results suggest that early antiviral treatment (as soon as possible after inception of infection) is needed to mitigate transmission, preventing 50% more infections compared to late treatment (started 3 to 5 days after symptoms onset). Our results highlight the synergistic effect of vaccination and antiviral treatment: as the vaccination rate increases, antivirals have a larger relative impact on population transmission. Finally, our model projects that even in highly vaccinated populations, adding antiviral treatment can be extremely helpful to mitigate COVID-19 deaths. Conclusions These results suggest that antiviral treatments can become a strategic tool that, in combination with vaccination, can significantly reduce COVID-19 hospitalizations and deaths and can help control SARS-Co
Source: BioMedCentral - 🏆 22. / 71 Read more »
Disney promises 'sneak peek' at Amy Hennig's Marvel game in SeptemberDisney has announced it's hosting a game-focused digital showcase this September, with a 'sneak peek' at Amy Hennig's n… This is a thing? Sounds like they're about announce something way to early again.
Source: eurogamer - 🏆 68. / 61 Read more »
Wicksteed Park celebrates centenary a year late due to CovidWicksteed Park is hosting a regatta and 1920s ball after its 100th birthday was affected by Covid. I went to Wicksteed with our Sunday School in The Early 60s from Wolverton Milton Keynes thanks Philip Gammage
Source: BBCNorthampton - 🏆 32. / 68 Read more »